Company Schedules Conference Call Wednesday, May 23rd at 11:00AM ET to Update Investors on MuGard Commercial Activities
ACCESS PHARMACEUTICALS, INC. (ACCP.OB), a biopharmaceutical company leveraging its  logo.png)
proprietary drug-delivery platforms to develop treatments in areas of oncology, diabetes, and RNAi, will host an investor call to update investors on MuGardcommercialization activities, including progress with pharmacy benefit managers, payers and pharmacy formularies, and other new developments within the program.
The investor conference call is scheduled to be held on Wednesday, May 23, 2012 at 11:00 am ET. Interested parties may participate by dialing 877-407-4019 (US) or 201-689-8337 (International) approximately five to ten minutes before the call start time.
A replay of the call will be available starting on May 23, 2012 at 1:00 pm ET, through June 6, 2012 until 11:59 pm ET. Interested parties may access the replay by dialing 877-660-6853 (US) or 201-612-7415 (International) and entering account number 383 and conference ID number 377785.
About MuGard:
MuGard is a novel; ready-to-use mucoadhesive oral wound rinse and coating for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatment of oral mucositis is estimated to be in excess of $1 billion world-wide. For more information, please visit www.MuGard.com.
About Access Pharmaceuticals:
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, ProLindac™, a second generation DACH Platinum in Phase 2 clinical testing of patients with ovarian cancer, and Thiarabine™, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas.
The company also has other advanced drug delivery technologies including CobaCyte™-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.
ProActive Capital Indexes
See ProActive's Disclaimer
Applied DNA Sciences Inc. (OTCBB: APDN; Twitter: $APDN) sells patented DNA security solutions to protect products, brands and intellectual property from counterfeiting and diversion. SigNature DNA is a botanical mark used to authenticate products in a unique manner that essentially cannot be copied, and provide a forensic chain of evidence that can be used to prosecute perpetrators.
The Company has announced its financial results for the second fiscal quarter ending March 31, 2012, generating revenues of $518,402, thus marking the company's highest recorded quarterly revenues, and the second sequential quarter to set this record.
Second Quarter Highlights include:
- Revenues increased slightly (0.3%), quarter over quarter, to $518,402, a new high for quarterly revenues previously established last quarter.
- Revenues increased 369% as compared to the same quarter in the prior fiscal year.
- Net loss dropped 36% as compared to the first quarter ending December 31, 2011.
- Net loss dropped 40%, as compared to the same quarter in the prior fiscal year.
- The six-month period of FY12 to-date has already exceeded (by 7%) total revenues of FY11.
- Revenues for the six-month period have increased by 126% year over year, topping $1 million for the first time.
- Net loss for the first six-month period increased slightly (0.3%) year over year.
Dr. James A. Hayward, President and CEO of Applied DNA Sciences, stated,
"The Company began FY '12 with an exciting first quarter. Our developments in the cash-in-transit, semiconductor authentication and textile and apparel authentication markets have sustained that momentum and contributed to the increase in our revenues. We intend to pursue both domestic and international sales opportunities in each of these vertical markets. We continue to increase our customer base. In addition, the initial responses to our new product lines, smartDNA® and digitalDNA™, have been encouraging."
Read the full release at Yahoo Finance.
ProActive Capital Indexes
See ProActive's Disclaimer
Pegasi Energy Resources Corp. (OTCBB:PGSI), a Nevada corporation (“PERC” or “Pegasi”), is an independent organic growth-oriented energy company engaged in the exploration and production of natural gas and oil through the development of a repeatable, low geological risk, high potential project in the active East Texas oil and gas region. Pegasi currently holds interests in properties located in Marion and Cass County, Texas, home to the giant Rodessa oil field, which has produced approximately 2.3 trillion cubic feet of gas and 400 million barrels of oil.
Caprock Risk Management ("CRM"), an independent research firm with expertise in the energy sector, has initiated research Coverage Of Pegasi. Caprock has initiated coverage on Pegasi with a STRONG BUY rating and a 12 month target of $1.50.
The report "examines the potential continued growth of the Company which is expected to be driven by strong revenue growth opportunities from its oil and gas production in the Highly Active East Texas Cotton Valley Liquids Trend. CRM's recommendation centers on strong secular trends for domestic oil production, Strong reserves in place, and large volumes of hydrocarbons in place in multiple geologic horizons combined with experienced, proven management with an average of over 30 years of experience specific to East Texas."
Chris Jarvis, CFA, CMT and Director of Research at Caprock Risk Management, commented,
"We are excited to launch coverage on Pegasi Resources Energy Corporation. We believe equity research plays a vital role and intermediary between investors and publicly traded companies, which makes the markets more efficient. In our opinion, Pegasi is an example of a publicly traded company with strong fundamentals that are not yet reflected in its share price. Given this, we believe Pegasi Energy validates the independent research model and are happy that Pegasi is one of several companies that we are launching coverage on in 2012."
Read more at Yahoo Finance.
ProActive Capital Indexes
See ProActive's Disclaimer
The First Annual Small Cap Investor Conference, presented by SeeThruEquity LLC, will be held on June 5, 2012 at The Cornell Club in midtown Manhattan. ProActive Newsroom is among the conference sponsors.
The conference will feature a very diverse audience of investors and an exceptional group of presenting companies, including:
- Acorn Energy, Inc. (NASDAQ: ACFN)
- Century Casinos Inc. (NASDAQ: CNTY)
- Harvard Bioscience, Inc. (NASDAQ: HBIO)
- Harris & Harris Group, Inc. (NASDAQ: TINY)
- PC Connection, Inc. (Nasdaq: PCCC)
- Telular Corp. (NASDAQ: WRLS)
More companies are expected. The conference schedule will be updated as companies confirm their attendance.
Each company will make a 30-minute presentation followed by a small group, Q&A breakout session. One-on-one meetings will be arranged between presenting companies and investors. Attendees will also have the opportunity to network with their peers, generating useful ideas and information.
Investors and equity research analysts may attend the conference without charge. To confirm your participation, please click HERE or email your response to conferences@seethruequity.com before June 1, 2012.
Registration will begin at 8am. The conference will start at 8:30am, and the last presentation will conclude at 4pm. A panel discussion led by leading industry professionals, a networking lunch hour, short networking breaks and a networking cocktail hour are also planned throughout the day.
Read more at SeeThruEquity.com.
ProActive Capital Indexes
See ProActive's Disclaimer
CytoSorbents Corporation (OTCBB: CTSO) is a critical care-focused therapeutic device company using blood purification to treat life-threatening illnesses. Its purification technology is based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and absorption.
The Company announced a corporate update as well as its financial results for the three months ended March 31, 2012.
Dr. Phillip Chan, Chief Executive Officer, stated,
"We have successfully achieved the majority of our goals in our controlled market release for CytoSorb® and are now putting the last pieces in place that will enable us to transition smoothly from a development stage company into one focused on early commercialization."
Dr. Chan provided updates regarding:
- Sales Development
- Sales Force
- Distribution outside of Germany
- Clinical Programs
- European Subsidiary
- Trademark, Marketing, and Website
- Research Programs
- Raising Capital, and
- Increasing Investor Awareness
He concluded,
"In all, with our small but growing team of dedicated professionals, we have been able to accomplish a significant number of major milestones over the past several years. As we wind down our controlled market release and transition towards a formal launch of CytoSorb® in Germany, I am confident that the experience we have gained during this time will help us execute well on our go-to-market strategy. I would encourage investors to keep focused on the longer-term prospects of the Company as we enter into this exciting early commercialization phase. We thank our employees and shareholders for their continued support and belief in the company."
Financial Results for the first quarter of 2012
CytoSorbents generated product revenues of $16,893 and $-0- for the three months ended March 31, 2012 and 2011, respectively. Revenues in the current quarter were part of an initial test market phase of CytoSorb® with the company exploring direct sales to hospitals inGermany and sales to distributor networks in other parts of Europe. The device was not available or approved for sale during the first quarter of 2011.
Our research and development costs were, $643,281 and $759,157, for the three months ended March 31, 2012 and 2011, respectively. The Company had net losses of $1,426,596 and $1,214,584 for the three month periods ended March 31, 2012 and 2011, respectively. Historically, our losses have resulted principally from costs incurred in the research and development of our polymer technology, and selling, general and administrative expenses, which together were $912,747 and $1,029,249 for the three month periods ended March 31, 2012 and 2011, respectively. The Company had $1,803,049 in cash at the end of the quarter.
For additional information please see the company's 10Q report for the period ended March 31, 2012 filed on May 15, 2012 on www.sec.gov.
Read the full release at SeekingAlpha.com.
ProActive Capital Indexes
See ProActive's Disclaimer
At Seeking Alpha, contributor ZetaKap wrote an article asking, "Interested in pharmaceutical companies? In search of companies that can manage their debt well? Do you prefer companies that can manage their long term debt? Are you after stocks that analysts are calling 'buy' or 'strong buy'? If so, you'll probably like this list."
Two of the six companies listed were Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) and Ventrus Biosciences (NASDAQ: VTUS).
About Keryx, ZetaKap wrote,
"Keryx Biopharmaceuticals Inc. has a Debt/Equity Ratio of 0.00 and Long Term Debt/Equity Ratio of 0.00 and Analysts' Rating of 1.80. The short interest was 13.77% as of 05/12/2012. Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, together with its subsidiaries, focuses on the acquisition, development, and commercialization of
pharmaceutical products for the treatment cancer and renal disease. The company's products under development include KRX-0401 (perifosine), an oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, as well as affects other pathways associated with programmed cell death, cell growth, cell differentiation, and cell survival. Its KRX-0401 is in Phase III clinical development stage for the treatment of refractory advanced colorectal cancer and multiple myeloma, as well as in Phase I and Phase II clinical development stages for the treatment of other tumor types."
About Ventrus Biosciences, ZetaKap writes,
"Ventrus Biosciences Inc. has a Debt/Equity Ratio of 0.00 and Long Term Debt/Equity Ratio of 0.00 and Analysts' Rating of 1.40. The short interest was 3.14% as of 05/12/2012. Ventrus Biosciences, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of late-stage prescription
drugs for gastrointestinal disorders, primarily hemorrhoidal disease, anal fissures, and fecal incontinence. It is developing three late-stage product candidates, including Iferanserin ointment (VEN 309) for the topical treatment of symptomatic internal hemorrhoids; Diltiazem cream (VEN 307), a topical treatment for the relief of pain associated with anal fissures; and Phenylephrine gel (VEN 308) for the treatment of fecal incontinence associated with ileal pouch anal anastomosis, an FDA orphan indication. The company was formerly known as South Island Biosciences, Inc."
Read the full article at SeekingAlpha.com.
ProActive Capital Indexes
See ProActive's Disclaimer
Pegasi Energy Resources Corp. (OTCBB:PGSI) is an independent organic growth-oriented energy company engaged in the exploration and production of natural gas and oil through the development of a repeatable, low geological risk, high potential project in the active East Texas oil and gas region. Pegasi currently holds interests in properties located in Marion and Cass County, Texas, home to the giant Rodessa oil field, which has produced approximately 2.3 trillion cubic feet of gas and 400 million barrels of oil.
The Company has several significant advantages over its competition, namely:
Leading acreage position in highly active East Texas Cotton Valley liquids trend. The Company's 20,000+ gross acreage position in the Cornerstone Project area make it one of a few entities to have effectively amassed large contiguous acreage blocks.
- Larger operators increasingly active in acquiring acreage.
Established production/proved reserves in high quality basin. Drilled 5 producing wells & established proved reserve base in Rodessa field w/ 21.4 bcfe of gross reserves & 1,166 mmcfe of current gross daily production.
- Large volumes of hydrocarbons in place in multiple geologic horizons.
- Strong platform to further grow our reserves and production.
Significant drilling inventory/long-term growth potential. Identified 109 locations on present acreage position.
- Continued development of properties allow us to increase our proved reserves and average daily production.
Significant infrastructure in place. 40-mile pipeline, established gathering system, & salt water disposal plant, contribute to maximizing cash flow.
- Ready access to several interstate pipelines & local end uses.
Experienced, proven management and operations team. Management team has average of 30+ years of experience in oil & natural gas industry.
Access to proprietary deal flow.
- Acquisition and leasing opportunities due to expertise in area & contacts.
Price: $0.85 - Mkt Cap: $46 m. - Revs (ttm): $1.19 million - Cash: $6.75, Debt: $8.35, PP&E: $22 m
Read more at PegasiEnergy.com.
ProActive Capital Indexes
See ProActive's Disclaimer
Onstream Media Corporation (Nasdaq: ONSM) is a leading online service provider of live and on-demand Internet broadcasting, corporate web communications and virtual marketplace technology. Onstream Media's innovative Digital Media Services Platform (DMSP) provides customers with cost effective tools for encoding, managing, indexing, and publishing content via the Internet.
The Company announced that its management will conduct a conference call at 4:30 p.m. ET on Wednesday, May 16, 2012, to discuss its second quarter fiscal 2012 financial results for the six and three months ended March 31, 2012. The Company anticipates releasing financial results and filing its Form 10-Q after the close of trading on the previous day, Tuesday, May 15, 2012.
During the call, company president and CEO Randy Selman and CFO Robert Tomlinson will discuss the Company's financial results as well as the outlook for the remainder of fiscal 2012. Management discussion will be followed by an open Q&A session.
Interested parties may listen to the presentation live online at http://www.visualwebcaster.com/event.asp?id=87123 or by calling 1-888-645-404 or 201-604-0169. It is recommended to dial in approximately 10 to 15 minutes prior to the scheduled start time. An audio rebroadcast of the conference call will be archived for one year online at http://www.visualwebcaster.com/event.asp?id=87123.
Read more at SeekingAlpha.com.
ProActive Capital Indexes
See ProActive's Disclaimer
BURLINGTON, Mass., May 15, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. 
(Nasdaq:CNDO - News), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of autoimmune diseases and cancer, today announced its financial results for the first quarter ended March 31, 2012.
Coronado reported a net loss of $6.6 million, or $0.35 per share, for the first quarter of 2012 compared to a net loss of $22.5 million, or $4.71 per share, for the first quarter of 2011. Included in the net loss for the first quarter of 2011 was an in-process research and development (R&D) expense of $20.7 million in connection with the acquisition of the TSO (Trichuris suis ova or CNDO-201) related assets.
Research and development expenses were $4.6 million for the three months ended March 31, 2012 compared to $1.2 million for the three months ended March 31, 2011. General and administrative (G&A) expenses totaled $2.0 million for the three months ended March 31, 2012 compared to $0.6 million for the three months ended March 31, 2011. In the three months ended March 31, 2012, R&D included expenses related to the TSO and CNDO-109 clinical programs, and G&A included expenses related to the company's infrastructure growth, increased business activity and becoming a publicly-traded entity. At March 31, 2012, Coronado's cash and cash equivalents totaled $17.7 million.
In April 2012, Coronado received from Dr. Falk Pharma GmbH (Falk), its development partner, a recommendation from the independent data monitoring committee that conducted an interim analysis (blinded to Falk) of clinical data from the initial 120 patients in Falk's Phase 2 trial evaluating TSO in Crohn's disease. "The Company is pleased with this development and we are using the information and recommendations derived from the interim analysis to finalize the design of our planned Phase 2 trial of TSO in Crohn's disease," said Dr. Bobby W. Sandage, Jr., Coronado's President and CEO. "Because the committee noted a positive efficacy trend and no safety concerns in addition to its sample size recommendations, we are planning dosage and sample size adjustments to maximize the probability of observing a TSO-treatment effect. We have been focused on moving our drug candidates into large-scale clinical trials. Pending final discussions with the FDA, we currently plan to commence the trial in the third quarter of 2012 and to have top-line study results in the second half of 2013."
Recent Corporate Highlights:
- Signed a Collaboration Agreement with Falk and OvaMed GmbH (OvaMed) for the development of TSO for Crohn's disease and obtained exclusive rights and licenses under certain Falk patent rights, pre-clinical data and clinical data from Falk's clinical trials of TSO in Crohn's disease, including an ongoing Phase 2 clinical trial, for use in North America, South America and Japan
- Hosted an Analyst & Investor Event in New York City with key opinion leaders in the fields of immunology, gastroenterology and oncology
- Strengthened senior management team through appointment of Lucy Lu, M.D., as Executive Vice President and Chief Financial Officer and the promotion of Karin Hehenberger, M.D., Ph.D., to Executive Vice President and Chief Medical Officer
Recent Scientific Highlights:
- Announced Phase 1 clinical trial results for TSO in Crohn's disease that demonstrated TSO is safe and well tolerated; oral presentation, entitled "Evaluation of Safety and Tolerability of Trichuris suis ova in Patients with Crohn's Disease," presented at the 8th International Congress on Autoimmunity
- Reported an Independent Data Monitoring Committee recommendation to continue the Falk Phase 2 Trial of TSO being conducted in Europe, noting no safety concerns and a positive efficacy trend; Falk adopted the committee's recommendations to increase the sample size and to conduct a subsequent interim analysis at the time the trial reaches approximately 250 patients
- Filed IND with the FDA for CNDO-109 to treat acute myeloid leukemia (AML); on track to initiate a Phase 1/2 allogeneic clinical trial for the treatment of patients with high risk AML in first complete remission in the second half of 2012
Conference Call and Webcast Information
Coronado management will review its first quarter financial results and development programs via conference call and webcast today at 8:30 AM ET. To participate in the conference call, please dial (877) 312-5413 (toll free from the US and Canada), or (253) 237-1511 (for international callers). Investors may also access a live audio webcast of the call at www.coronadobiosciences.com on the Events & Webcasts page.
A replay of the webcast will be available shortly after the conclusion of the call. The webcast archive will remain available for one year. An audio replay will also be available shortly after the conclusion of the call and will be made available until May 23, 2012. The audio replay can be accessed by dialing (855) 859-2056 (toll free from the US and Canada), or (404) 537-3406 (for international callers) and entering Event ID 80148097.
About Coronado Biosciences
Coronado Biosciences is engaged in the development of novel immunotherapy biologic agents. The company's two principal pharmaceutical product candidates in clinical development are: TSO (Trichuris suis ova or CNDO-201), a biologic for the treatment of autoimmune diseases, such as Crohn's disease, ulcerative colitis and multiple sclerosis; and CNDO-109, a biologic that activates natural killer (NK) cells, for the treatment of acute myeloid leukemia (AML) and solid tumors. For more information, please visit www.coronadobiosciences.com.
Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the company's product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated risks relating to the results of research and development activities, uncertainties relating to preclinical and clinical testing, financing and strategic agreements and relationships, the early stage of products under development, our need for substantial additional funds, government regulation, patent and intellectual property matters; our dependence on third party suppliers and competition, as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
| |
| |
| CORONADO BIOSCIENCES, INC. AND SUBSIDIARY |
| (A development stage enterprise) |
| Consolidated Balance Sheets |
| ($ in thousands) |
| (Unaudited) |
| |
|
|
| |
March 31, |
December 31, |
| |
2012 |
2011 |
| ASSETS |
|
|
| Cash and cash equivalents |
$ 17,735 |
$ 23,160 |
| Prepaid and other current assets |
308 |
215 |
| Total Assets |
$ 18,043 |
$ 23,375 |
| |
|
|
| LIABILITIES AND STOCKHOLDERS' EQUITY |
|
|
| Current liabilities |
$ 3,843 |
$ 3,493 |
| Debt |
750 |
750 |
| Total Liabilities |
4,593 |
4,243 |
| Stockholders' Equity |
13,450 |
19,132 |
| Total Liabilities and Stockholders' Equity |
$ 18,043 |
$ 23,375 |
| |
| |
| CORONADO BIOSCIENCES, INC. AND SUBSIDIARY |
| (A development stage enterprise) |
| Consolidated Statements of Operations |
| ($ in thousands except for share and per share amounts) |
| (Unaudited) |
| |
|
|
| |
For the three months ended |
| |
March 31, |
| |
2012 |
2011 |
| Operating expenses: |
|
|
| Research and development |
$ 4,581 |
$ 1,246 |
| General and administrative |
2,000 |
593 |
| In-process research and development |
-- |
20,706 |
| Loss from operations |
(6,581) |
(22,545) |
| Interest income |
44 |
19 |
| Interest expense |
(19) |
(17) |
| Net loss |
$ (6,556) |
$ (22,543) |
| Basic and diluted net loss per common share |
$ (0.35) |
$ (4.71) |
| Weighted average common shares outstanding--basic and diluted |
18,604,245 |
4,791,102 |
Contact:
Investor Relations
Lucy Lu, MD, Executive Vice President
& Chief Financial Officer
Coronado Biosciences, Inc.
781-238-6619; ir@coronadobio.com
Marcy Nanus, Vice President
The Trout Group, LLC.
646-378-2927; mnanus@troutgroup.com
Media Relations
Dennis S. Dobson Jr., CEO
Dobson Media Group
203-258-0159; dobsonpr@erols.com
ProActive Capital Indexes
See ProActive's Disclaimer
NEW YORK, May 15, 2012 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS - News), a pharmaceutical company focused on developing and commercializing gastrointestinal products, announced today that Dr. Russell Ellison, Chairman and Chief Executive Officer, will be presenting at the Bank of America Merrill Lynch 2012 Health Care Conference on Wednesday, May 16 at 3:40 pm (Pacific Time) at the Encore at Wynn in Las Vegas.
Additionally, the Company will be hosting one-on-one meetings throughout the day. Institutional investors that would like to request a meeting should contact ventrus@argotpartners.com. A live audio webcast and replay of the presentation will be available on the "Investors" section of the Company's website.
http://investor.ventrusbio.com/events.cfm
Contact:
Ventrus BioSciences, Inc.
David Barrett
646-706-5208
dbarrett@ventrusbio.com
Argot Partners
David Pitts
212-600-1902
david@argotpartners.com
ProActive Capital Indexes
See ProActive's Disclaimer